HCM: Rounding Bottom detected on 8 Oct 2026

HCM is forming a rounding bottom pattern following earlier bullish pennant and flat base structures, indicating consolidation after recent gains. Current price at $14.28 sits 46% above 52-week lows but 13% below recent highs, with key resistance at $15.85 and support at $9.77. The pattern quality scores 70 overall (structure: 11/15, breakout: 13/13, volume: 12/12), signaling solid technical setup. RSI at 56.68 suggests room to run without overbought conditions. Volume ratio of 0.94x confirms sufficient participation, though below average relative to 20-day mean.

Recent catalysts include the submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-driven EGFR-mutated lung cancer on September 28, 2026, with AstraZeneca seeking US approval. On September 3, 2026, HUTCHMED signed an exclusive GSK agreement granting development and commercialization rights for HMPL-A830 outside Mainland China, Hong Kong, Macau and Taiwan. The first patient in this global Phase Ia trial received a dose on September 24, 2026. H1 2026 oncology product revenue grew 23% to $121.4 million, and the company reiterated full-year 2026 Oncology/Immunology revenue guidance of $330–$450 million. Multiple analyst upgrades occurred in September, with Bank of America maintaining a Buy rating at $18.00 target (29.5% upside).

A successful breakout above resistance at $15.85 would target the conservative measured move of $15.07, representing modest 5.5% upside from current levels. The 68.96% win probability suggests historical patterns of this type break upward roughly 69% of the time. Volume confirmation near recent 62k-share 20-day average would validate the breakout. Invalidation occurs on a close below key support at $9.77, which would represent a 31.6% downside loss and signal pattern failure. The breakout scenario aligns with technical recovery following recent September consolidation.

Healthcare sector regime scores moderately at 0.59, below the overall market's 0.95 bullish score—suggesting sector headwinds. Goldman Sachs initiated a Hold rating at $14.00 target in July 2026, implying minimal upside, creating conflicting analyst signals despite multiple Buy ratings. Low beta of 0.3 indicates defensive characteristics, but elevated 20-day volatility of 46% creates potential for whipsaws on news flow. The upcoming ESMO presentation of Phase III lung cancer data carries execution risk. Cash position of $1.37 billion provides runway, but China-regulatory and geopolitical exposure warrants monitoring given US approval pathway complexity for ORPATHYS combination.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.